X

Trial Profile

Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Jul 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mogamulizumab (Primary)
Indications Mycosis fungoides; Sezary syndrome
Focus Adverse reactions
Sponsors Kyowa Kirin; Kyowa Kirin Pharmaceutical Development

Most Recent Events

27 Apr 2023 Status changed from recruiting to active, no longer recruiting.
11 Apr 2022 Planned End Date changed from 1 Mar 2024 to 1 May 2025.
11 Apr 2022 Planned primary completion date changed from 1 Jan 2024 to 1 May 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com